Prism Medico & Pharmacy Ltd.

As of June 30, 2026, Prism Medico & Pharmacy Ltd. carries a market capitalization of 393.34M, placing it among publicly traded companies globally. Its enterprise value stands at 393.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Prism Medico & Pharmacy Ltd. has 13.56M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 46.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 393.34M versus a market cap of 393.34M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Prism Medico & Pharmacy Ltd. recorded 1.18M in income tax expense. The company reported a pretax loss of -2.79M and -3.97M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Prism Medico & Pharmacy Ltd.'s stock has gained approximately 49.14% over the past 52 weeks. The 50-day moving average sits at 29.61, while the 200-day moving average is 26.76.

Over the twelve months ended June 30, 2026, Prism Medico & Pharmacy Ltd. generated 8.55M in revenue and converted that into -3.97M in net income, yielding earnings per share of -0.64. EBITDA reached -3.89M, while operating income came in at -3.92M.

Over the twelve months ended June 30, 2026, Prism Medico & Pharmacy Ltd. posted a gross margin of 16.78, reflecting its pricing power and cost economics. The operating margin of -45.90 and net profit margin of -46.47 provide insight into operational efficiency.